search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Expressie van CCL25 en CCR9 bij inflammatoire darmziekten en primaire scleroserende cholangitis.


- candidate number9331
- NTR NumberNTR2851
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR13-apr-2011
- Secondary IDsMEC 09/059 METC AMC
- Public TitleExpressie van CCL25 en CCR9 bij inflammatoire darmziekten en primaire scleroserende cholangitis.
- Scientific TitleExpression of CCL25 and CCR9 in human colon in IBD/PSC patients.
- ACRONYMPSColon
- hypothesisPrimary sclerosing cholangitis (PSC) is a rare chronic cholestatic disease of unknown cause. Chronic inflammation leads to bile duct destruction resulting in liver failure. PSC is regarded as an immune dysbalance disease. PSC has a strong association with IBD, especially ulcerative colitis and some consider PSC as an extraintestinal manifestation of IBD. The gut-homing lymphocyte paradigm offers a plausible explanation linking the gut and liver in PSC.
- Healt Condition(s) or Problem(s) studiedCrohn's disease, Ulcerative Colitis, Inflammatory bowel disease, Primary sclerosing cholangitis
- Inclusion criteria1. Newly diagnosed PSC patients screened for IBD, ≥18 yr old;
2. a. Newly diagnosed UC patients, ≥18 yr old;
2. b. Infectious enterocolitis patients (bacterial/viral/parasitic), ≥18 yr old;
3. PSC/UC surveillance patients, ≥18 yr old;
4. UC surveillance patients, ≥18 yr old;
5. Controls referred for CRC screening, ≥18 yr old.
- Exclusion criteria1. Inability to give informed consent;
2. Bleeding diathesis.
- mec approval receivedyes
- multicenter trialno
- randomisedno
- groupParallel
- Type2 or more arms, non-randomized
- Studytypeobservational
- planned startdate 1-mei-2009
- planned closingdate31-dec-2011
- Target number of participants80
- InterventionsIleal and colonic biopsies during colonoscopy.
- Primary outcomeExpression of CCL25 in human colon.
- Secondary outcome1. Semiquantitative analyses of CCL25 and/or CCR9+ lymphocytes in double stained colonic biopsies between patients and controls;
2. Quantitative analyses of CCL25 mRNA in colon of patients and controls;
3. Quantitative analyses α4β7/CCR9+ T cells in peripheral blood.
- TimepointsOne timepoint: PBMC isolation and biopsy collection during colonoscopy.
- Trial web siteN/A
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIESDrs. K. Boonstra
- CONTACT for SCIENTIFIC QUERIESMD. PhD. C. IJ. Ponsioen
- Sponsor/Initiator Academic Medical Center (AMC), Department of Hepato- and Gastroenterology
- Funding
(Source(s) of Monetary or Material Support)
Academic Medical Center (AMC), Department of Hepato- and Gastroenterology
- PublicationsN/A
- Brief summaryRationale:
Primary sclerosing cholangitis (PSC) is a rare chronic cholestatic disease of unknown cause. Chronic inflammation leads to bile duct destruction resulting in liver failure. PSC is regarded as an immune dysbalance disease. PSC has a strong association with IBD, especially ulcerative colitis and some consider PSC as an extraintestinal manifestation of IBD. The gut-homing lymphocyte paradigm offers a plausible explanation linking the gut and liver in PSC.

Primary objective:
To demonstrate and compare expression of CCL25 and CCR9+ lymphocytes in peripheral blood and colon of PSC-, PSC/IBD-, IBD-, gastroenteritis patients and controls.

Study design:
Exploratory case control study.

Study population:
1. Newly diagnosed PSC patients screened for IBD, ≥18 yr old;
2. a. Newly diagnosed UC patients, ≥18 yr old;
2. b. Infectious enterocolitis patients (bacterial/viral/parasitic), ≥18 yr old;
3. PSC/UC surveillance patients, ≥18 yr old;
4. UC surveillance patients, ≥18 yr old;
5. Controls referred for CRC screening, ≥18 yr old.

Main study parameters/endpoints:
1. Expression of CCL25 in human colon by immunohistochemistry;
2. Difference in proportion of CCL25 and/or CCR9+ lymphocytes in double stained colonic biopsies between patients and controls;
3. Quantitative analyses of CCL25 mRNA expression in colon of patients and controls;
4. Quantitative analyses α4β7/CCR9+ T cells in peripheral blood.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
Colonic biopsies are obtained during surveillance colonoscopy at the Department of Gastroenterology and Hepatology AMC. 8 specimens at 3 levels, 24 specimens in total per patient. During standard surveillance colonoscopy procedure 32 biopsies are obtained for pathological analyses. The additive burden consists of 24 additional biopsies. One extra blood sample is drawn prior to colonoscopy.
- Main changes (audit trail)
- RECORD13-apr-2011 - 20-apr-2011


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl